126 related articles for article (PubMed ID: 32693135)
21. Combination treatment of ligustrazine piperazine derivate DLJ14 and adriamycin inhibits progression of resistant breast cancer through inhibition of the EGFR/PI3K/Akt survival pathway and induction of apoptosis.
Chen J; Wang W; Wang H; Liu X; Guo X
Drug Discov Ther; 2014 Feb; 8(1):33-41. PubMed ID: 24647156
[TBL] [Abstract][Full Text] [Related]
22. Immunostimulatory Effects of Chitooligosaccharides on RAW 264.7 Mouse Macrophages via Regulation of the MAPK and PI3K/Akt Signaling Pathways.
Yang Y; Xing R; Liu S; Qin Y; Li K; Yu H; Li P
Mar Drugs; 2019 Jan; 17(1):. PubMed ID: 30626153
[TBL] [Abstract][Full Text] [Related]
23. Astaxanthin targets PI3K/Akt signaling pathway toward potential therapeutic applications.
Zarneshan SN; Fakhri S; Farzaei MH; Khan H; Saso L
Food Chem Toxicol; 2020 Nov; 145():111714. PubMed ID: 32871194
[TBL] [Abstract][Full Text] [Related]
24. Activation of the PI3K-AKT-mTOR signaling pathway promotes DEHP-induced Hep3B cell proliferation.
Chen X; Qin Q; Zhang W; Zhang Y; Zheng H; Liu C; Yang Y; Xiong W; Yuan J
Food Chem Toxicol; 2013 Sep; 59():325-33. PubMed ID: 23793038
[TBL] [Abstract][Full Text] [Related]
25. Repression of Human Papillomavirus Oncogene Expression under Hypoxia Is Mediated by PI3K/mTORC2/AKT Signaling.
Bossler F; Kuhn BJ; Günther T; Kraemer SJ; Khalkar P; Adrian S; Lohrey C; Holzer A; Shimobayashi M; Dürst M; Mayer A; Rösl F; Grundhoff A; Krijgsveld J; Hoppe-Seyler K; Hoppe-Seyler F
mBio; 2019 Feb; 10(1):. PubMed ID: 30755508
[TBL] [Abstract][Full Text] [Related]
26. Carboxymethylated chitosan stimulates proliferation of Schwann cells in vitro via the activation of the ERK and Akt signaling pathways.
He B; Liu SQ; Chen Q; Li HH; Ding WJ; Deng M
Eur J Pharmacol; 2011 Sep; 667(1-3):195-201. PubMed ID: 21699895
[TBL] [Abstract][Full Text] [Related]
27. Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors.
Andersen JN; Sathyanarayanan S; Di Bacco A; Chi A; Zhang T; Chen AH; Dolinski B; Kraus M; Roberts B; Arthur W; Klinghoffer RA; Gargano D; Li L; Feldman I; Lynch B; Rush J; Hendrickson RC; Blume-Jensen P; Paweletz CP
Sci Transl Med; 2010 Aug; 2(43):43ra55. PubMed ID: 20686178
[TBL] [Abstract][Full Text] [Related]
28. Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer.
Bradford LS; Rauh-Hain A; Clark RM; Groeneweg JW; Zhang L; Borger D; Zukerberg LR; Growdon WB; Foster R; Rueda BR
Gynecol Oncol; 2014 May; 133(2):346-52. PubMed ID: 24561032
[TBL] [Abstract][Full Text] [Related]
29. Emodin negatively affects the phosphoinositide 3-kinase/AKT signalling pathway: a study on its mechanism of action.
Olsen BB; Bjørling-Poulsen M; Guerra B
Int J Biochem Cell Biol; 2007; 39(1):227-37. PubMed ID: 17018259
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine.
Xie X; Tang B; Zhou J; Gao Q; Zhang P
Oncol Rep; 2013 Aug; 30(2):773-82. PubMed ID: 23743572
[TBL] [Abstract][Full Text] [Related]
31. Recent development in targeting PI3K-Akt-mTOR signaling for anticancer therapeutic strategies.
Qazi AK; Hussain A; Hamid A; Qurishi Y; Majeed R; Ahmad M; Najar RA; Bhat JA; Singh SK; Zargar MA; Ali S; Saxena AK
Anticancer Agents Med Chem; 2013 Dec; 13(10):1552-64. PubMed ID: 23438828
[TBL] [Abstract][Full Text] [Related]
32. Research progress on the PI3K/AKT signaling pathway in gynecological cancer (Review).
Shi X; Wang J; Lei Y; Cong C; Tan D; Zhou X
Mol Med Rep; 2019 Jun; 19(6):4529-4535. PubMed ID: 30942405
[TBL] [Abstract][Full Text] [Related]
33. Antitumor activity of curcumin by modulation of apoptosis and autophagy in human lung cancer A549 cells through inhibiting PI3K/Akt/mTOR pathway.
Liu F; Gao S; Yang Y; Zhao X; Fan Y; Ma W; Yang D; Yang A; Yu Y
Oncol Rep; 2018 Mar; 39(3):1523-1531. PubMed ID: 29328421
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in Breast Cancer Cells.
Ji Y; Di W; Yang Q; Lu Z; Cai W; Wu J
Clin Lab; 2015; 61(8):1043-51. PubMed ID: 26427150
[TBL] [Abstract][Full Text] [Related]
35. Targeting PI3K/Akt/mTOR signaling pathway by polyphenols: Implication for cancer therapy.
Mirza-Aghazadeh-Attari M; Ekrami EM; Aghdas SAM; Mihanfar A; Hallaj S; Yousefi B; Safa A; Majidinia M
Life Sci; 2020 Aug; 255():117481. PubMed ID: 32135183
[TBL] [Abstract][Full Text] [Related]
36. Hydrazinocurcumin and 5-fluorouracil enhance apoptosis and restrain tumorigenicity of HepG2 cells via disrupting the PTEN-mediated PI3K/Akt signaling pathway.
Zhou Y; Zhang M; Zhang Z; Jia Y; Zhang C; Peng L
Biomed Pharmacother; 2020 Sep; 129():109851. PubMed ID: 32559627
[TBL] [Abstract][Full Text] [Related]
37. Phosphatidylinositol 3-kinase/Akt signaling as a key mediator of tumor cell responsiveness to radiation.
Toulany M; Rodemann HP
Semin Cancer Biol; 2015 Dec; 35():180-90. PubMed ID: 26192967
[TBL] [Abstract][Full Text] [Related]
38. Twist promotes reprogramming of glucose metabolism in breast cancer cells through PI3K/AKT and p53 signaling pathways.
Yang L; Hou Y; Yuan J; Tang S; Zhang H; Zhu Q; Du YE; Zhou M; Wen S; Xu L; Tang X; Cui X; Liu M
Oncotarget; 2015 Sep; 6(28):25755-69. PubMed ID: 26342198
[TBL] [Abstract][Full Text] [Related]
39. PI3K/ Akt/ mTOR Pathway as a Therapeutic Target for Colorectal Cancer: A Review of Preclinical and Clinical Evidence.
Narayanankutty A
Curr Drug Targets; 2019; 20(12):1217-1226. PubMed ID: 31215384
[TBL] [Abstract][Full Text] [Related]
40. Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells.
Chen KF; Chen HL; Tai WT; Feng WC; Hsu CH; Chen PJ; Cheng AL
J Pharmacol Exp Ther; 2011 Apr; 337(1):155-61. PubMed ID: 21205925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
